Negev Labs
Kostia Adamsky is an accomplished executive with extensive experience in operations and innovation within the pharmaceutical sector. Currently serving as Chief Operational Officer at Ariadne Bio and COO & co-founder of Negev Labs since 2022, Kostia also holds the position of Principal at Negev Capital. Previous roles include VP Technology and Operations at LEVCO Pharmaceuticals and VP Operations at Regenera Pharma, where Kostia also acted as Chief Executive Officer. Co-founding Targia Pharmaceuticals, which focuses on CNS drug reformulation, and serving as Co-CEO further highlights Kostia's entrepreneurial spirit. Educational credentials include an M.Sc. and Ph.D. in Biochemistry and Biology from the Weizmann Institute of Science, alongside a Bachelor's degree in Life Science from Tel Aviv University.
This person is not in any teams
This person is not in any offices
Negev Labs
Negev Labs is a biotech platform company that is focused on the development of neuroplastogens, a novel class of neuroplasticity-promoting compounds that may provide significant clinical benefit in a wide range of indications. Neuroplastogens are new chemical entities that harness the cellular mechanisms of psychedelics but are non-hallucinogenic and bypass the need for in-clinic administration, offering improved therapeutic scalability and patentability. Negev Labs is rapidly advancing with several families of novel neuroplastogens in psychiatric and non-psychiatric diseases, including affective disorders, schizophrenia, neurology, and ophthalmology. The Company’s primary program is expected to commence Phase 1b trials in the third quarter of 2024, with ten additional projects in various stages of pre-clinical development and discovery. Negev Labs was founded by the team behind Negev Capital, a VC with investments in more than 20 psychedelics-focused biotech companies. Utilizing its extensive network, it has built a collaborative community involving over 500 leading researchers in the domain. Negev Labs continuously sources and screens projects from its network, selecting those with the most potential to develop novel therapeutics that can generate real impact for patients. Negev’s methodology includes progressing these compounds through its preclinical platform to achieve Proof of Concept (PoC) in humans. Following successful PoC studies, Negev will either seek to license them to pharmaceutical companies or establish them as standalone companies.